The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report 2025
Synopsis
The global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor was valued at US$ 5551 million in the year 2024 and is projected to reach a revised size of US$ 9999 million by 2031, growing at a CAGR of 8.9% during the forecast period.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PARP (Poly ADP-Ribose Polymerase) Inhibitor.
The PARP (Poly ADP-Ribose Polymerase) Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
Segment by Application
Ovarian Cancer
Breast Cancer
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor was valued at US$ 5551 million in the year 2024 and is projected to reach a revised size of US$ 9999 million by 2031, growing at a CAGR of 8.9% during the forecast period.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PARP (Poly ADP-Ribose Polymerase) Inhibitor.
The PARP (Poly ADP-Ribose Polymerase) Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
Segment by Application
Ovarian Cancer
Breast Cancer
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Overview
1.1 Product Definition
1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value Comparison by Type (2024 VS 2031)
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
1.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Application (2024 VS 2031)
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Estimates and Forecasts
1.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2020-2031
1.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2020-2031
1.4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competition by Manufacturers
2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2020-2025)
2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2020-2025)
2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Type & Application
2.7 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Enter into This Industry
2.8 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation and Trends
2.8.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue
2.8.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Scenario by Region
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2020-2031
3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2020-2025
3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2026-2031
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2020-2031
3.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2020-2025
3.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2026-2031
3.4 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.4.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
3.4.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.5.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
3.5.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2031)
3.6.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.7.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
3.7.3 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
3.8.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2031)
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2026-2031)
4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2031)
4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2020-2031)
4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2020-2025)
4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2026-2031)
4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2020-2031)
4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2020-2031)
5 Segment by Application
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2031)
5.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2025)
5.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2026-2031)
5.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2031)
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2020-2031)
5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2020-2025)
5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2026-2031)
5.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2020-2031)
5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Tesaro
6.2.1 Tesaro Company Information
6.2.2 Tesaro Description and Business Overview
6.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.2.5 Tesaro Recent Developments/Updates
6.3 Merck & Co
6.3.1 Merck & Co Company Information
6.3.2 Merck & Co Description and Business Overview
6.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.3.5 Merck & Co Recent Developments/Updates
6.4 Clovis Oncology
6.4.1 Clovis Oncology Company Information
6.4.2 Clovis Oncology Description and Business Overview
6.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.4.5 Clovis Oncology Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 GSK
6.6.1 GSK Company Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 Zai Lab
6.7.1 Zai Lab Company Information
6.7.2 Zai Lab Description and Business Overview
6.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.7.5 Zai Lab Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Chain Analysis
7.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process Analysis
7.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Marketing
7.4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels
7.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
7.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer Analysis
8 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
8.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
8.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
8.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
8.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation by Manufacturers in 2024
Table 4. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2020-2025)
Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Type & Application
Table 12. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2025) & (K Units)
Table 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2020-2025)
Table 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2026-2031) & (K Units)
Table 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2026-2031)
Table 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2020-2025)
Table 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2026-2031)
Table 25. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units)
Table 27. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units)
Table 28. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units)
Table 32. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units)
Table 33. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units)
Table 42. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units)
Table 43. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2020-2025)
Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2026-2031)
Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2025)
Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2026-2031)
Table 54. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Type (2020-2025)
Table 55. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Type (2026-2031)
Table 56. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2020-2025)
Table 57. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2026-2031)
Table 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2020-2025)
Table 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2026-2031)
Table 60. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Application (2020-2025)
Table 61. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Application (2026-2031)
Table 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2025)
Table 63. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2026-2031)
Table 64. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Application (2020-2025)
Table 65. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Application (2026-2031)
Table 66. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2020-2025)
Table 67. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2026-2031)
Table 68. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2020-2025)
Table 69. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2026-2031)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Tesaro Company Information
Table 76. Tesaro Description and Business Overview
Table 77. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 79. Tesaro Recent Developments/Updates
Table 80. Merck & Co Company Information
Table 81. Merck & Co Description and Business Overview
Table 82. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 84. Merck & Co Recent Developments/Updates
Table 85. Clovis Oncology Company Information
Table 86. Clovis Oncology Description and Business Overview
Table 87. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 89. Clovis Oncology Recent Developments/Updates
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 94. Pfizer Recent Developments/Updates
Table 95. GSK Company Information
Table 96. GSK Description and Business Overview
Table 97. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 99. GSK Recent Developments/Updates
Table 100. Zai Lab Company Information
Table 101. Zai Lab Description and Business Overview
Table 102. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 104. Zai Lab Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
Table 108. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List
Table 109. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends
Table 110. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
Table 111. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
Table 112. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Product Picture of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type: 2024 & 2031
Figure 4. Lynparza Product Picture
Figure 5. Zejula Product Picture
Figure 6. Rubraca Product Picture
Figure 7. Talzenna Product Picture
Figure 8. Other Product Picture
Figure 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application: 2024 & 2031
Figure 11. Ovarian Cancer
Figure 12. Breast Cancer
Figure 13. Other
Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (2020-2031) & (US$ Million)
Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2020-2031) & (K Units)
Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit) & (2020-2031)
Figure 18. PARP (Poly ADP-Ribose Polymerase) Inhibitor Report Years Considered
Figure 19. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Manufacturers in 2024
Figure 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest PARP (Poly ADP-Ribose Polymerase) Inhibitor Players: Market Share by Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2024
Figure 22. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031)
Figure 25. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2020-2031)
Figure 26. U.S. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031)
Figure 29. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2020-2031)
Figure 30. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2020-2031)
Figure 37. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Taiwan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Indonesia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Thailand PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Malaysia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Philippines PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031)
Figure 48. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2020-2031)
Figure 49. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2020-2031)
Figure 54. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type (2020-2031)
Figure 58. Global Revenue Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type (2020-2031)
Figure 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2020-2031)
Figure 60. Global Sales Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application (2020-2031)
Figure 61. Global Revenue Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application (2020-2031)
Figure 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2020-2031)
Figure 63. PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
